Herpes zoster, the viral infection better known as shingles, can leave patients with chronic pain, nerve damage, and other severe complications—but a widely available vaccine offers strong protection, according to global health authorities. With cases rising among older adults and immunocompromised populations, experts emphasize that vaccination remains the most effective way to prevent shingles and its debilitating aftermath, including postherpetic neuralgia (PHN), which affects up to 30% of patients over 60.
While shingles typically appears as a painful rash, its long-term effects can be life-altering. “The vaccine isn’t just about avoiding a rash—it’s about preventing years of nerve pain that can disrupt daily life,” said Dr. Anne A. Gershon, professor of pediatrics at Columbia University and a leading shingles researcher. “For people over 50, the risk of complications rises sharply, yet vaccination rates remain unacceptably low in many countries.”
This article examines the latest evidence on shingles risks, vaccine efficacy, and why experts now consider it a critical preventive measure—especially as new data emerges on its benefits for immunocompromised individuals.
Why Shingles Poses a Greater Threat Than Many Realize
Herpes zoster reactivates the varicella-zoster virus (VZV), the same pathogen that causes chickenpox. After an initial infection, the virus lies dormant in nerve cells and can re-emerge years later as shingles, particularly in people with weakened immune systems or those over 50. While shingles affects an estimated 1 in 3 people in the U.S. by age 60, its complications are often underestimated.
Key risks include:
- Postherpetic neuralgia (PHN): Persistent nerve pain lasting months or years, reported in 10–30% of cases, with higher rates in older adults.
- Vision loss: If shingles affects the eye (ophthalmic zoster), it can lead to permanent blindness in 1–2% of cases without prompt treatment.
- Neurological damage: Rare but severe complications like meningitis or stroke, particularly in immunocompromised patients.
Dr. Gershon notes that “the pain from PHN can be so severe that some patients describe it as worse than childbirth. Yet many people still believe shingles is just a minor rash.”
Vaccine Efficacy: How Well Does It Work?
The two shingles vaccines currently approved—Shingrix (recombinant vaccine) and the older Zostavax (live attenuated)—offer significant protection, but their effectiveness varies by age and health status.
Clinical trials and real-world data show:
- Shingrix: 90% effective in preventing shingles in adults 50–69, and 97% effective in those 70+. It also reduces PHN risk by 88–91%.
- Zostavax: 51% effective in preventing shingles in adults 60+, with 67% effectiveness in those 70+.
The World Health Organization (WHO) recommends Shingrix for all adults 50 and older, regardless of prior shingles infection, due to its superior protection. “The data is clear: Shingrix is the gold standard,” said Dr. Mark H. Sawyer, professor of pediatrics at UC San Diego. “It’s not just about preventing shingles—it’s about preventing the lifelong consequences.”
Who Should Get Vaccinated—and When?
Vaccination guidelines vary by country, but global health authorities agree on key recommendations:
- Age 50+: The CDC and WHO recommend Shingrix for all adults 50 and older, even if they’ve had shingles before. “The virus can reactivate multiple times,” explains Dr. Gershon. “Vaccination provides long-term immunity.”
- Immunocompromised individuals: People with HIV, cancer, or on immunosuppressive drugs should receive Shingrix, as their risk of severe shingles is 3–5 times higher than the general population.
- Timing: Shingrix requires two doses, given 2–6 months apart. The first dose provides 70% protection after 10 days, with full immunity developing after the second dose.
In the EU, Shingrix is approved for adults 18 and older with weakened immune systems, reflecting growing recognition of its role beyond age-based prevention. “We’re seeing a shift toward broader recommendations, especially as we learn more about shingles in younger immunocompromised patients,” said Dr. Fischer.
Misconceptions That Keep Vaccination Rates Low
Despite the evidence, shingles vaccination rates remain below 50% in many countries. Common myths include:
- “I already had chickenpox, so I’m safe.” While nearly everyone has VZV from childhood chickenpox, the virus can reactivate decades later as shingles.
- “Shingles is just a rash—I can handle it.” Up to 30% of patients develop PHN, which can last years and require strong pain medications.
- “The vaccine has bad side effects.” While Shingrix can cause temporary pain at the injection site or mild fever, serious side effects are rare (1 in 10,000).
- “I’m too young to worry.” Shingles can affect people in their 40s, especially those with underlying health conditions.
Dr. Sawyer emphasizes that “the vaccine is safe, effective, and far less risky than the complications of shingles. Yet many people still don’t prioritize it.”
What Happens Next: Updates and Ongoing Research
Research into shingles prevention is evolving, with new developments on the horizon:
- Booster doses: Studies are underway to determine if a third Shingrix dose could provide longer-lasting immunity, particularly for immunocompromised patients.
- Vaccine access: The WHO’s 2023 recommendation for Shingrix inclusion in national immunization programs aims to expand global access.
- Pediatric shingles: While rare, children can develop shingles, particularly if immunocompromised. The CDC recommends vaccination for those with weakened immune systems.
The next major checkpoint for shingles research will be the FDA’s 2025 review of Shingrix’s long-term safety data, which could influence booster guidelines. In the meantime, experts urge immediate action: “Don’t wait until you get shingles to consider the vaccine,” said Dr. Gershon. “The protection is strongest before exposure.”
Key Takeaways: What You Need to Know
- Shingles is more than a rash: Up to 30% of patients develop chronic nerve pain (PHN), which can last years.
- Vaccination is highly effective: Shingrix reduces shingles risk by 90%+ in adults 50+ and PHN risk by 88–91%.
- Timing matters: The vaccine works best before exposure. Two doses are required for full protection.
- It’s not just for seniors: Immunocompromised individuals of any age should be vaccinated.
- Side effects are mild: Temporary pain or fever are common, but serious reactions are rare.
- Global recommendations: The WHO and CDC now advise Shingrix for all adults 50+, regardless of prior shingles.
For the latest updates on shingles vaccination, consult your healthcare provider or national health authorities. In the U.S., visit the CDC’s shingles page. For global guidance, refer to the WHO’s shingles fact sheet.
Have you or a loved one experienced shingles? Share your story in the comments—or help raise awareness by sharing this article with someone who may benefit from vaccination.